Abstract
Pirfenidone, an antifibrotic tissue growth antagonist, is in development for the potential treatment of fibrotic diseases including renal, liver and pulmonary fibrosis and for multiple sclerosis.
MeSH terms
-
Animals
-
Clinical Trials as Topic
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Fibrosis / drug therapy*
-
Humans
-
Pyridones / adverse effects
-
Pyridones / pharmacokinetics
-
Pyridones / pharmacology
-
Pyridones / therapeutic use*
-
Structure-Activity Relationship